Circulating tumor and immune cells for minimally invasive risk stratification of smoldering multiple myeloma
- Termini, Rosalinda
- Zihala, David
- Terpos, Evangelos
- Pérez-Montaña, Albert
- Jelinek, Tomas
- Raab, Marc
- Weinhold, Niels
- Mai, Elias K
- Grab, Anna Luise
- Corre, Jill
- Vergez, Francois
- Sacco, Antonio
- Chiarini, Marco
- Giustini, Viviana
- Tucci, Alessandra
- Rodríguez, Sara
- Moreno, Cristina
- Perez, Cristina
- Maia, Catarina
- Martin-Sanchez, Esperanza
- Guerrero, Camila
- Botta, Cirino
- Garcés, Juan-Jose
- Lopez, Aitziber
- Tamariz-Amador, Luis-Esteban
- Prósper, Felipe
- Bargay, Joan
- Cabezudo, Maria-Elena
- Ocio, Enrique M
- Hájek, Roman
- Martinez-Lopez, Joaquin
- Solano, Fernando
- Iglesias, Rebeca
- Paiva, Artur
- Geraldes, Catarina
- Matos Silva, Helena
- Gomez, Clara
- De Arriba, Felipe
- Ludwig, Heinz
- Garcia-Guiñon, Antoni
- Casanova, Maria
- Alegre, Adrian
- Cabañas, Valentin
- Sirvent, Maialen
- Oriol, Albert
- De la Rubia, Javier
- Hernández-Rivas, José-Ángel
- Palomera, Luis
- Sarasa, Maria
- Rios, Pablo
- Puig, Noemi
- Mateos, Maria-Victoria
- Flores-Montero, Juan
- Orfao, Alberto
- Goldschmidt, Hartmut
- Avet-Loiseau, Herve
- Roccaro, Aldo M
- San-Miguel, Jesus F
- Paiva, Bruno
Publication date
September 2022
DOI Publisher
American Association for Cancer Research (AACR)Abstract
Early intervention in smoldering multiple myeloma (SMM) requires optimal risk stratification to avoid under and over-treatment. We hypothesized that replacing bone marrow (BM) plasma cells (PCs) for circulating tumor cells (CTCs), and adding immune biomarkers in peripheral blood (PB) for the identification of patients at risk of progression due to lost immune surveillance, could improve the International Myeloma Working Group 20/2/20 model
.jpg%3Fwidth%3D300&w=3840&q=75)
Add to ORKG